FDG PET/CT KOD SUMNJE NA RECIDIV KARCINOMA GRLIĆA MATERICE
Sažetak
Karcinom grlića materice predstavlja četvrti najčešći malignitet i četvrti uzrok smrti od tumora kod žena u svetu, i približno trećina žena lečenih od cervikalnog karcinoma razviće recidiv bolesti tokom praćenja. U praćenju i kod sumnje na recidiv cervikalnog karcinoma koriste se različite imidžing metode kao što su CT, MR i PET/CT. Međutim, uloga PET/CT je u konstantom porastu kod ovih pacijenata i najnoviji Vodič Nacionalne sveobuhvatne mreže za rak (National Comprehensive Cancer Network - NCCN) ipak preporučuje PET/CT kao metodu izbora u praćenju pacijenata sa II-IV stadijumom bolesti, kao i kod sumnje na recidiv ili metastatsku bolest. PET/CT je pokazao veću senzitivnost i specifičnost u odnosu na konvencionalni imidžing kod bolesnica sa sumnjom na recidiv karcinoma grlića materice, naročito u evaluaciji udaljene bolesti. Dodatna prednost PET/CT kod ovih pacijenata je njegov uticaj na odluku o terapiji kod približno polovine slučajeva. PET/CT je takođe pokazao prognostičku ulogu u predikciji preživljavanja bez pojave progresije kao i ukupnog preživljavanja, s obzirom da pacijenti sa sumnjom na recidiv cervikalnog karcinoma koji imaju pozitivan nalaz na PET/CT imaju značajno lošiju prognozu.
Reference
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249.
2. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:22-36.
3. Miljuš D, Živković Perišić S, Božić Z, editors. Malignant tumours in Republic of Serbia: 2020. Serbian Cancer Registry. Belgrade: Institute of Public Health of Serbia “Dr Milan Jovanović Batut”; 2022.
4. de Foucher T, Bendifallah S, Ouldamer L, Bricou A, Lavoue V, Varinot J, et al. Patterns of recurrence and prognosis in locally advanced FIGO stage IB2 to IIB cervical cancer: Retrospective multicentre study from the FRANCOGYN group. Eur J Surg Oncol. 2019 Apr;45(4):659-665.
5. Schieda N, Malone SC, Al Dandan O, Ramchandani P, Siegelman ES. Multi-modality organ-based approach to expected imaging findings, complications and recurrent tumour in the genitourinary tract after radiotherapy. Insights Imaging. 2014 Feb;5(1):25-40.
6. Thomas GM, Dembo AJ, Myhr T, Black B, Pringle JF, Rawlings G. Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery. Int J Gynecol Cancer. 1993 Jul;3(4):193-198.
7. Gandy N, Arshad MA, Park WE, Rockall AG, Barwick TD. FDG-PET Imaging in Cervical Cancer. Semin Nucl Med. 2019 Nov;49(6):461-470.
8. Petrović J, Macut Đ, Šobić Šaranović D. Radionuclide imaging of neuroendocrine tumors. MedPodml. 2020 Apr 12;71(3):36-42.
9. Palaniswamy SS, Borde CR, Subramanyam P. 18F-FDG PET/CT in the evaluation of cancer cervix: Where do we stand today? Nucl Med Commun. 2018 Jul;39(7):583-592.
10. Meads C, Davenport C, Małysiak S, Kowalska M, Zapalska A, Guest P, et al. Evaluating PET-CT in the detection and management of recurrent cervical cancer: systematic reviews of diagnostic accuracy and subjective elicitation. BJOG. 2014 Mar;121(4):398-407.
11. Chu Y, Zheng A, Wang F, Lin W, Yang X, Han L, et al. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis. Nucl Med Commun. 2014 Feb;35(2):144-150.
12. Ding XP, Feng L, Ma L. Diagnosis of recurrent uterine cervical cancer: PET versus PET/CT: a systematic review and meta-analysis. Arch Gynecol Obstet. 2014 Oct;290(4):741-747.
13. Peng NJ, Hu C, Chiu YL, Yu CC, Li CJ, Sheu JJ, et al. Detection of Recurrent Cervical Cancer and Prediction of Its Patient Survival with Serum Squamous-Cell Carcinoma-Antigen and 2-[18F] Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography/Computed Tomography. Diagnostics (Basel). 2020 Aug 31;10(9):657.
14. Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Sugimura K. Performance of FDG-PET/CT for diagnosis of recurrent uterine cervical cancer. Eur Radiol. 2008 Oct;18(10):2040-7.
15. Patel-Lippmann K, Robbins JB, Barroilhet L, Anderson B, Sadowski EA, Boyum J. MR Imaging of Cervical Cancer. Magn Reson Imaging Clin N Am. 2017 Aug;25(3):635-649.
16. Bjurberg M, Brun E. Clinical impact of 2-deoxy-2-[18F]fluoro-D-glucose (FDG)-positron emission tomography (PET) on treatment choice in recurrent cancer of the cervix uteri. Int J Gynecol Cancer. 2013 Nov;23(9):1642-1646.
17. Pallardy A, Bodet-Milin C, Oudoux A, Campion L, Bourbouloux E, Sagan C, et al. Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1270-1278.
18. Lai CH, Huang KG, See LC, Yen TC, Tsai CS, Chang TC, et al. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography. Cancer. 2004 Feb 1;100(3):544-552.
19. Yen TC, Lai CH, Ma SY, Huang KG, Huang HJ, Hong JH, et al. Comparative benefits and limitations of 18F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer. Eur J Nucl Med Mol Imaging. 2006 Dec;33(12):1399-1407.
20. Chung HH, Jo H, Kang WJ, Kim JW, Park NH, Song YS, et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol. 2007 Mar;104(3):529-534.
21. Zhou Z, Liu X, Hu K, Zhang F. The clinical value of PET and PET/CT in the diagnosis and management of suspected cervical cancer recurrence. Nucl Med Commun. 2018 Feb;39(2):97-102.
22. Chung HH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, et al. Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer. Eur J Radiol. 2012 Aug;81(8):e817-e822.